About Us

Our story dates back to 2010 when Prof. Anna-Lena Spetz's pioneering research took an unexpected turn. The serendipitous finding of oligo TIR-01 opened doors to a new realm of possibilities in immunotherapy.

The discovery was met with enthusiasm and support from the Stockholm University incubator, setting the stage for the birth of TIRmed in 2018. At TIRmed, we envision a world where immunomodulatory advancements lead to healthier, happier lives without the need for continuous treatments.

With unwavering dedication to our research and a deep sense of responsibility towards our discoveries, we are poised to make a significant impact on the field of immunotherapy.As we continue to push the boundaries of a new generation of oligonucleotide treatments, we invite you to join us on this journey.

Together, we can revolutionize the way we combat diseases, improve patient outcomes, and make a lasting difference in the world of medicine.